2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

SAUL, a Single-Arm Study of Atezolizumab for Chemotherapy-Pretreated Locally Advanced or Metastatic Carcinoma of the Urinary Tract: Outcomes by Key Baseline Factors, PD-L1 Expression and Prior Platinum Therapy - Beyond the Abstract

Immune checkpoint inhibition represents a new standard in the treatment of platinum-refractory advanced urothelial cancer. These therapies result in long-term benefit in a small subset of patients but there are no reliable tools to identify those patients who may benefit. A subanalysis of the SAUL phase IIIB study showed that apart from the Bellmunt risk algorithm, time-from-last chemotherapy, prior perioperative chemotherapy, and PD-L1 expression impacted overall survival after 2nd-line therapy with atezolizumab.


SAUL, a Single-Arm Study of Atezolizumab for Chemotherapy-Pretreated Locally Advanced or Metastatic Carcinoma of the Urinary Tract: Outcomes by Key Baseline Factors, PD-L1 Expression and Prior Platinum Therapy - Beyond the Abtract



Aristotelis Bamias, MD, PhD, MRCP, Professor of Therapeutics-Internal Medicine-Oncology, National & Kapodistrian University of Athens, Director of 2nd Propaedeutic Dept of Medicine, ATTIKON University Hospital

Read the Abstract